NO20051406L - Indolderivater som beta-2 agonister - Google Patents

Indolderivater som beta-2 agonister

Info

Publication number
NO20051406L
NO20051406L NO20051406A NO20051406A NO20051406L NO 20051406 L NO20051406 L NO 20051406L NO 20051406 A NO20051406 A NO 20051406A NO 20051406 A NO20051406 A NO 20051406A NO 20051406 L NO20051406 L NO 20051406L
Authority
NO
Norway
Prior art keywords
indole derivatives
agonists
beta
disorders
preparation
Prior art date
Application number
NO20051406A
Other languages
English (en)
Norwegian (no)
Inventor
Mark Edward Bunnage
Justin Stephen Bryans
Alan Daniel Brown
Paul Alan Glossop
Charlotte Alice Louise Lane
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20020292513 external-priority patent/EP1407769A1/fr
Priority claimed from EP03290069A external-priority patent/EP1440966A1/fr
Application filed by Pfizer filed Critical Pfizer
Publication of NO20051406L publication Critical patent/NO20051406L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
NO20051406A 2002-10-11 2005-03-17 Indolderivater som beta-2 agonister NO20051406L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20020292513 EP1407769A1 (fr) 2002-10-11 2002-10-11 Derivés d'indole comme beta-2 agonistes
EP03290069A EP1440966A1 (fr) 2003-01-10 2003-01-10 Dérivés d'indole utilisables pour traiter des maladies
PCT/IB2003/004441 WO2004032921A1 (fr) 2002-10-11 2003-10-06 Derives d'indole utilises comme agonistes beta-2

Publications (1)

Publication Number Publication Date
NO20051406L true NO20051406L (no) 2005-04-22

Family

ID=32095049

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051406A NO20051406L (no) 2002-10-11 2005-03-17 Indolderivater som beta-2 agonister

Country Status (25)

Country Link
EP (1) EP1556034B1 (fr)
JP (1) JP4490911B2 (fr)
KR (1) KR20050047552A (fr)
AP (1) AP2005003283A0 (fr)
AR (1) AR041566A1 (fr)
AT (1) ATE392206T1 (fr)
AU (1) AU2003269316A1 (fr)
BR (1) BR0315234A (fr)
CA (1) CA2499314C (fr)
CO (1) CO5550421A2 (fr)
DE (1) DE60320439T2 (fr)
EA (1) EA200500618A1 (fr)
EC (1) ECSP055780A (fr)
ES (1) ES2302938T3 (fr)
IS (1) IS7751A (fr)
MA (1) MA27452A1 (fr)
MX (1) MXPA05003866A (fr)
NO (1) NO20051406L (fr)
OA (1) OA12938A (fr)
PA (1) PA8586001A1 (fr)
PE (1) PE20040775A1 (fr)
PL (1) PL376396A1 (fr)
TW (1) TW200424171A (fr)
UY (1) UY28013A1 (fr)
WO (1) WO2004032921A1 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
EP1460064A1 (fr) 2003-03-14 2004-09-22 Pfizer Limited Derivés de Indole-2-carboxamide comme beta-2 agonistes
GB0312832D0 (en) * 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005092841A1 (fr) * 2004-03-23 2005-10-06 Pfizer Limited Composes presentant une activite beta-agoniste
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EA016203B1 (ru) 2006-03-20 2012-03-30 Пфайзер Лимитед Производные амина
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
TW200821316A (en) 2006-07-19 2008-05-16 Astrazeneca Ab Novel compounds 243
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008075005A1 (fr) 2006-12-19 2008-06-26 Astrazeneca Ab Dérivés quinuclidinol utilisés en tant qu'antagonistes du récepteur muscarinique
DE602007011670D1 (de) 2007-01-10 2011-02-10 Irm Llc Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer
US20100239551A1 (en) 2007-02-09 2010-09-23 Irm Llc Compounds and compositions as channel activating protease inhibitors
US8318935B2 (en) 2007-05-07 2012-11-27 Novartis Ag Organic compounds 75074
EP2231280B1 (fr) 2007-12-10 2016-08-10 Novartis AG Pyrazine carboxamides semblable à l'Amiloride en tant que bloqueurs d'ENaC
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
WO2009138707A1 (fr) 2008-05-13 2009-11-19 Astrazeneca Ab Dérivés de quinuclidine utilisés comme antagonistes des récepteurs muscariniques m3
RU2509077C2 (ru) 2008-05-27 2014-03-10 Астразенека Аб Феноксипиридиниламидные производные и их применение в лечении pde4-опосредованных болезненных состояний
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010067102A1 (fr) 2008-12-09 2010-06-17 Astrazeneca Ab Dérivés de diazaspiro[5.5]undécane et composés associés utilisés comme antagonistes des récepteurs muscariniques et agonistes des récepteurs bêta adrénergiques dans le traitement des affections pulmonaires
EP2379507B1 (fr) 2008-12-30 2013-10-16 Pulmagen Therapeutics (Inflammation) Limited Composés de sulfonamide pour le traitement de troubles respiratoires
WO2010150014A1 (fr) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
EP2813227A1 (fr) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions pour le traitement de la mucoviscidose et d'autres maladies chroniques
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011061527A1 (fr) 2009-11-17 2011-05-26 Astrazeneca Ab Combinaisons qui comprennent un modulateur du récepteur glucocorticoïde, destinées au traitement de maladies respiratoires
WO2011098746A1 (fr) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
KR20140014184A (ko) 2011-02-25 2014-02-05 아이알엠 엘엘씨 Trk 억제제로서의 화합물 및 조성물
AR085509A1 (es) 2011-03-09 2013-10-09 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
EA022342B1 (ru) 2011-06-10 2015-12-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
MX369311B (es) 2012-12-06 2019-11-05 Chiesi Farm Spa Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico.
AR093832A1 (es) 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
AR099336A1 (es) 2014-02-17 2016-07-13 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
KR20220019015A (ko) 2019-06-10 2022-02-15 노파르티스 아게 Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체
UY38860A (es) 2019-08-28 2021-02-26 Novartis Ag Derivados de 1,3–fenil heteroarilo sustituidos, composiciones para su uso en el tratamiento de enfermedades y formas cristalinas
WO2021260441A1 (fr) 2020-06-26 2021-12-30 Mylan Pharma Uk Limited Formulations comprenant du (5-[3-(3-hydroxyphénoxy)azétidin-1-yl]-5-méthyl-2,2-diphénylhexanamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029290A1 (fr) * 1993-06-14 1994-12-22 Pfizer Inc. Amines secondaires utilisees comme agents antidiabete et anti-obesite
EP0801060A1 (fr) * 1996-04-09 1997-10-15 Pfizer Inc. Des agonistes bèta-3 adrénergiques hétérocycliques
EP0822185A1 (fr) * 1996-07-31 1998-02-04 Pfizer Inc. Agonistes bèta-3-adrénergiques en tant qu'agents antidiabète et anti-obésité

Also Published As

Publication number Publication date
ECSP055780A (es) 2005-08-11
PE20040775A1 (es) 2004-12-10
BR0315234A (pt) 2005-08-23
AU2003269316A1 (en) 2004-05-04
KR20050047552A (ko) 2005-05-20
JP4490911B2 (ja) 2010-06-30
IS7751A (is) 2005-03-17
PL376396A1 (en) 2005-12-27
EA200500618A1 (ru) 2005-12-29
PA8586001A1 (es) 2005-02-04
DE60320439T2 (de) 2009-05-20
MA27452A1 (fr) 2005-07-01
AP2005003283A0 (en) 2005-06-30
DE60320439D1 (de) 2008-05-29
MXPA05003866A (es) 2005-06-22
EP1556034A1 (fr) 2005-07-27
ES2302938T3 (es) 2008-08-01
UY28013A1 (es) 2004-04-30
AR041566A1 (es) 2005-05-18
JP2006511596A (ja) 2006-04-06
CA2499314A1 (fr) 2004-04-22
CO5550421A2 (es) 2005-08-31
EP1556034B1 (fr) 2008-04-16
OA12938A (en) 2006-10-13
CA2499314C (fr) 2010-08-24
WO2004032921A1 (fr) 2004-04-22
ATE392206T1 (de) 2008-05-15
TW200424171A (en) 2004-11-16

Similar Documents

Publication Publication Date Title
NO20051406L (no) Indolderivater som beta-2 agonister
MXPA05013059A (es) Derivados de 2-amino-piridina como agonistas del adrenoceptor beta-2.
WO2004080964A8 (fr) Derives d'indole utiles pour traiter des maladies
NO20084005L (no) Aminderivater
MXPA05012840A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
NO20092342L (no) Azaspiroderivativater
WO2007058832A3 (fr) INHIBITEURS DES KINASES Tec
EA200900337A1 (ru) Сульфонамидные производные в качестве адренергических агонистов и мускариновых антагонистов
TW200505865A (en) Compounds useful for the treatment of diseases
EA200601462A1 (ru) Соединения для лечения заболеваний
NO20061292L (no) Heterosyldiske forbindelser og fremgangsmater for fremstilling og anvendelse derav
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
WO2005090287A3 (fr) Composes convenant pour le traitement de maladies
NO20092413L (no) Pyrazolanaloger
NO20064806L (no) Formamidderivater anvendelige som adenoceptor
NO20064805L (no) Sammensetninger for behandling av sykdommer
UA86615C2 (en) Formamide derivatives useful as adrenoceptor
TNSN06302A1 (en) Composes pour le traitement de maladies
NO20063875L (no) Forbindelser som anvendes for behandling av sykdommer